Concepedia

Gurudatt Chandorkar

GC

14

Publications

973

Citations

13

H-Index

2000

Active since

Affiliations

Cubist Pharmaceuticals (United States)(Current)

Vertex Pharmaceuticals (United States)

University of Kansas

Gurudatt Chandorkar is an author at Cubist Pharmaceuticals (United States) specializing in medicine, pharmacology, and pharmacotherapy.

Top concepts

Publications per year

2000–2017

14

Publications

14

Preclinical Profile of VX-950, a Potent, Selective, and Orally Bioavailable Inhibitor of Hepatitis C Virus NS3-4A Serine Protease

Robert B. Perni, Susan J. Almquist, Randal A. Byrn et al. · Antimicrobial Agents and Chemotherapy · 2006 · 382 citations · Full text

Intrapulmonary penetration of ceftolozane/tazobactam and piperacillin/tazobactam in healthy adult subjects

Gurudatt Chandorkar, Jennifer A. Huntington, Mark H. Gotfried et al. · Journal of Antimicrobial Chemotherapy · 2012 · 118 citations · Full text

Functional expression of P-glycoprotein in primary cultures of human cytotrophoblasts and BeWo cells☆

Naoki Utoguchi, Gurudatt Chandorkar, Michael L. Avery et al. · Reproductive Toxicology · 2000 · 75 citations · Full text

, , +12

Impact of Renal Function on the Pharmacokinetics and Safety of Ceftolozane-Tazobactam

Myra Wooley, Benjamin Miller, Gopal Krishna et al. · Antimicrobial Agents and Chemotherapy · 2014 · 72 citations · Full text

Population pharmacokinetics of ceftolozane/tazobactam in healthy volunteers, subjects with varying degrees of renal function and patients with bacterial infections

Gurudatt Chandorkar, Alan Xiao, Samer Mouksassi et al. · The Journal of Clinical Pharmacology · 2014 · 63 citations · Full text

, , +18

Rows per page

1–5 of 14